LANREOTIDE
Clinical Indication
Monotherapy for the treatment of symptomatic non-localised autosomal dominant polycystic liver disease
Comments
Date of classification
October 2026
Red
Medicines which should be prescribed only in a specialist setting usually within a secondary or tertiary care service. NB: Some highly specialised RED medicines e.g. injectable treatments for cancer are not included on the LLR APC website list.